Skip to main content
Premium Trial:

Request an Annual Quote

Tekmira, Collaborators Secure $2.4M Grant to Develop Ebola, Marburg Treatments


Tekmira Pharmaceuticals said this week that it and collaborators at the University of Texas Medical Branch have received a $2.4 million grant from the National Institutes of Health to develop RNAi therapeutics against Ebola and Marburg hemorrhagic fever viral infections.

According to the company, the grant will support the use of its lipid nanoparticle delivery technology to develop the therapeutics.

Tekmira recently named an RNAi-based Ebola treatment, dubbed TKM-EBOLA, as its third clinical candidate (GSN 8/19/2010).

"The NIH grant is consistent with our strategy of leveraging external funding to advance our [lipid nanoparticle] technology and product candidates in certain infectious diseases, including Ebola and Marburg," Tekmira President and CEO Mark Murray said in a statement.

Earlier this year, Tekmira published data showing that siRNAs, delivered using the company's stable nucleic acid lipid particles, could completely protect rhesus macaques from a lethal dose of Ebola (GSN 6/3/2010).

Also this year, the company received a contract worth up to $140 million from the US Department of Defense Chemical and Biological Defense Program to develop TKM-EBOLA.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.